Liposomal Irinotecan Hydrochloride
Phase 2Small molecule
Liposomal Irinotecan Hydrochloride is one of 61 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
714 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Camptosar
EEastern Cooperative Oncology Group
Phase 3
S-1 Plus CDDP
Taiho Pharmaceutical Co., Ltd.Phase 3
Gemzar
Johnson & JohnsonPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Liposomal Irinotecan Hydrochloride
ZZhejiang Cancer Hospital
Phase 2
S1,
CChinese Academy of Medical Sciences
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Induction Phase1
GenmabPreclinical
Glutamine
SanofiPreclinical
Human Albumin
TTonghua Anrate Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- ZZhejiang Cancer Hospital